Top-Line Results For Sanofi/Genzyme's MS Drug Lemtrada Leave Investors Wanting More
This article was originally published in The Pink Sheet Daily
Executive Summary
Alemtuzumab scores a win in reducing relapse rates, but doesn't best interferon beta-1a at preventing disability in first of two crucial Phase III studies due to report this year.
You may also be interested in...
Sanofi/Genzyme MS Drug Lemtrada Scores High Against Rebif
Genzyme, a Sanofi company, set the bar high for its multiple sclerosis contender by stacking it up against Roche’s interferon beta-1a in Phase III trials and got the results it was looking for, with a filing set for this quarter.
Sanofi/Genzyme MS Drug Lemtrada Scores High Against Rebif
Genzyme, a Sanofi company, set the bar high for its multiple sclerosis contender by stacking it up against Roche’s interferon beta-1a in Phase III trials and got the results it was looking for, with a filing set for this quarter.
Biogen Idec’s BG-12 Results Up The Ante In The Oral MS Market
The competitive profile of Biogen Idec Inc.’s BG-12 in the highly coveted and burgeoning market for oral multiple sclerosis drugs got a big boost April 21 with the release of better-than-expected additional monotherapy data from the Phase III DEFINE study.